[go: up one dir, main page]

ATE423110T1 - Verbindungen, zusammensetzungen und verfahren zur behandlung von zellulären proliferativen erkrankungen - Google Patents

Verbindungen, zusammensetzungen und verfahren zur behandlung von zellulären proliferativen erkrankungen

Info

Publication number
ATE423110T1
ATE423110T1 AT03764801T AT03764801T ATE423110T1 AT E423110 T1 ATE423110 T1 AT E423110T1 AT 03764801 T AT03764801 T AT 03764801T AT 03764801 T AT03764801 T AT 03764801T AT E423110 T1 ATE423110 T1 AT E423110T1
Authority
AT
Austria
Prior art keywords
compounds
proliferative diseases
compositions
methods
cellular proliferative
Prior art date
Application number
AT03764801T
Other languages
English (en)
Inventor
Andrew Mcdonald
David Morgans
Gustave Bergnes
Dashyant Dhanak
Steven Knight
Original Assignee
Cytokinetics Inc
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytokinetics Inc, Smithkline Beecham Corp filed Critical Cytokinetics Inc
Application granted granted Critical
Publication of ATE423110T1 publication Critical patent/ATE423110T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/34—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D309/36—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • C07D309/38—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms one oxygen atom in position 2 or 4, e.g. pyrones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrane Compounds (AREA)
AT03764801T 2002-07-17 2003-07-17 Verbindungen, zusammensetzungen und verfahren zur behandlung von zellulären proliferativen erkrankungen ATE423110T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US39669002P 2002-07-17 2002-07-17

Publications (1)

Publication Number Publication Date
ATE423110T1 true ATE423110T1 (de) 2009-03-15

Family

ID=30116052

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03764801T ATE423110T1 (de) 2002-07-17 2003-07-17 Verbindungen, zusammensetzungen und verfahren zur behandlung von zellulären proliferativen erkrankungen

Country Status (7)

Country Link
US (2) US6949538B2 (de)
EP (1) EP1539727B1 (de)
JP (1) JP2005533119A (de)
AT (1) ATE423110T1 (de)
AU (1) AU2003252025A1 (de)
DE (1) DE60326248D1 (de)
WO (1) WO2004006865A2 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04010240A (es) 2002-04-17 2005-06-08 Cytokinetics Inc Compuestos, composiciones y metodos.
US6949538B2 (en) 2002-07-17 2005-09-27 Cytokinetics, Inc. Compounds, compositions, and methods
EP1554265A4 (de) * 2002-09-13 2008-05-07 Cytokinetics Inc Verbindungen, zusammensetzungen und verfahren
WO2006018628A1 (en) * 2003-03-07 2006-02-23 Astrazeneca Ab Enantiomers of selected fused pyrimidones and uses in the treatment and preventi on of cancer
DK1601673T3 (da) * 2003-03-07 2009-08-24 Astrazeneca Ab Kondenserede heterocykler og anvendelser af disse
EP1670456A2 (de) * 2003-10-06 2006-06-21 Cytokinetics, Inc. Verbindungen, zusammensetzungen und verfahren
WO2005113507A1 (en) 2004-05-21 2005-12-01 Novartis Vaccines And Diagnostics Inc. Substituted quinoline derivatives as mitotic kinesin inhibitors
TW200612958A (en) 2004-06-18 2006-05-01 Chiron Corp Substituted imidazole derivatives
JP2008506759A (ja) * 2004-07-22 2008-03-06 アストラゼネカ アクチボラグ 癌の処置および予防に有用な縮合ピリミドン類
BRPI0514390A (pt) * 2004-08-18 2008-06-10 Astrazeneca Ab enanciÈmero de um composto ou um sal farmacêuticamente aceitável ou um éster hidrolisável in vivo do mesmo, uso do mesmo, métodos para o tratamento de cáncer, para produzir um efeito inibidor de eg5 em um animal de sangue quente e para tratar doenças, e, composição farmacêutica
US20060041128A1 (en) * 2004-08-18 2006-02-23 Astrazeneca Ab Selected fused heterocyclics and uses thereof
EP1807399A2 (de) 2004-10-19 2007-07-18 Novartis Vaccines and Diagnostics, Inc. Indol- und benzimidazolderivate
CN101084194A (zh) * 2004-12-21 2007-12-05 默克公司 有丝分裂驱动蛋白抑制剂
JP2009514866A (ja) * 2005-11-02 2009-04-09 サイトキネティクス・インコーポレーテッド ある種の化学物質、組成物、および方法
US7902240B2 (en) 2006-11-13 2011-03-08 Novartis Ag Substituted pyrazole and triazole compounds as KSP inhibitors
CA2674318A1 (en) 2007-01-05 2008-07-17 Novartis Ag Cyclized derivatives as eg-5 inhibitors

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3177130D1 (de) * 1980-08-30 1990-01-11 Hoechst Ag Aminosaeurederivate, verfahren zu ihrer herstellung, diese enthaltende mittel und deren verwendung.
US4434296A (en) * 1982-05-17 1984-02-28 The Upjohn Company Process for preparing intermediates for antiatherosclerotic compounds
US4434295A (en) 1982-05-17 1984-02-28 The Upjohn Company Anti-atherosclerotic 6,7-dihydro-7,7-disubstituted-khellin analogs
US4482558A (en) * 1982-06-18 1984-11-13 Pfizer Inc. Antifungal amide and urea derivatives of (3-amino-2-aryl-2-hydroxyprop-1-yl)-1H-1,2,4-triazoles
JPS62201882A (ja) * 1985-11-18 1987-09-05 Yamanouchi Pharmaceut Co Ltd イソフラボン誘導体
IN164232B (de) * 1986-04-11 1989-02-04 Hoechst India
IL85554A0 (en) * 1987-03-02 1988-08-31 Takeda Chemical Industries Ltd Chromone derivatives
JPH0753725B2 (ja) * 1987-10-08 1995-06-07 富山化学工業株式会社 ４ｈ―１―ベンゾピラン―４―オン誘導体およびその塩、それらの製造法並びにそれらを含有する抗炎症剤
IL89840A (en) 1988-04-06 1996-10-31 Lipha Substituted flavonoid compounds and salts thereof their preparation and pharmaceutical composition containing them
USH1427H (en) 1988-04-06 1995-04-04 Briet; Phillipe Substituted flavonoid compounds, their salts, their manufacture and their use in combination with interleukin-2
US5304548A (en) * 1988-08-16 1994-04-19 The Upjohn Company Bivalent ligands effective for blocking ACAT enzyme for lowering plasma triglycerides and for elevating HDL cholesterol
US5180717A (en) * 1988-08-16 1993-01-19 The Upjohn Company Bivalent ligands effective for blocking ACAT enzyme for lowering plasma triglycerides and for elevating HDL cholesterol
US5284856A (en) * 1988-10-28 1994-02-08 Hoechst Aktiengesellschaft Oncogene-encoded kinases inhibition using 4-H-1-benzopyran-4-one derivatives
DE3836676A1 (de) 1988-10-28 1990-05-03 Hoechst Ag Die verwendung von 4h-1-benzopyran-4-on-derivaten, neue 4h-1-benzopyran-4-on-derivate und diese enthaltende arzneimittel
US5703075A (en) * 1988-12-21 1997-12-30 Pharmacia & Upjohn Company Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones
JPH04502322A (ja) 1988-12-21 1992-04-23 ジ・アップジョン・カンパニー 抗アテローム性動脈硬化症性および抗血栓性１―ベンゾピラン―４―オン類および２―アミノ―１，３―ベンゾオキサジン―４―オン類
US4977162A (en) * 1989-07-13 1990-12-11 Rorer Pharmaceutical Corporation Quinolinyl-chromone derivatives and use for treatment of hypersensitive ailments
US5082849A (en) * 1989-07-13 1992-01-21 Huang Fu Chich Quinolinyl-benzopyran derivatives as antagonists of leukotriene D4
US5215989A (en) * 1989-12-08 1993-06-01 Merck & Co., Inc. Nitrogen-containing heterocyclic compounds as class III antiarrhythmic agents
US5032598A (en) * 1989-12-08 1991-07-16 Merck & Co., Inc. Nitrogens containing heterocyclic compounds as class III antiarrhythmic agents
ES2106783T3 (es) 1990-06-20 1997-11-16 Upjohn Co 1-benzopiran-4-onas y 2-amino-1,3-benzoxacin-4-onas antiarterosclerosis y antitromboticas.
ATE161837T1 (de) * 1990-07-25 1998-01-15 Teijin Ltd Benzopyran derivat, seine darstellung und pharmazeutische zusammensetzung, welche dieses enthält
AU8506791A (en) 1990-10-01 1992-04-28 Janssen Pharmaceutica N.V. Novel 4-piperidinylcarbonyl derivatives
US5605896A (en) * 1992-02-25 1997-02-25 Recordati S.A., Chemical And Pharmaceutical Company Bicyclic heterocyclic derivatives having α1 adrenergic and 5HT1A activities
FR2693196B1 (fr) 1992-07-03 1994-12-23 Lipha Dérivés de benzopyranone ou de benzothiopyranone, procédé de préparation et composition pharmaceutique les contenant.
WO1995022992A2 (en) * 1994-02-23 1995-08-31 Chiron Corp Method and compositions for increasing the serum half-life of pharmacologically active agents
JPH10501256A (ja) * 1994-06-10 1998-02-03 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー Ｃ−４アミド置換化合物およびその治療剤としての使用
US5607928A (en) * 1994-08-05 1997-03-04 Zeneca Limited Carbapenem derivatives containing a bicyclic ketone substituent and their use as anti-infectives
GB9417969D0 (en) 1994-09-07 1994-10-26 King S College London Alkaloids and derivatives thereof
US5602171A (en) * 1995-06-07 1997-02-11 Sugen Inc. Methods of inhibiting phosphatase activity and treatment of disorders associated therewith using naphthopyrones and derivatives thereof
WO1997014419A1 (en) 1995-10-20 1997-04-24 Flora Inc. Transdermal delivery of alpha adrenoceptor blocking agents
US5908934A (en) 1996-09-26 1999-06-01 Bristol-Myers Squibb Company Process for the preparation of chiral ketone intermediates useful for the preparation of flavopiridol and analogs
GB9807779D0 (en) 1998-04-09 1998-06-10 Ciba Geigy Ag Organic compounds
US6087385A (en) 1998-10-30 2000-07-11 University Of Mississippi Flavonoid derivatives
US6028088A (en) * 1998-10-30 2000-02-22 The University Of Mississippi Flavonoid derivatives
DE19850131A1 (de) 1998-10-30 2000-05-04 Merck Patent Gmbh Chromenon- und Chromanonderivate
DE19858341A1 (de) * 1998-12-17 2000-06-21 Merck Patent Gmbh Chromanderivate
GB9911071D0 (en) 1999-05-12 1999-07-14 Darwin Discovery Ltd Hydroxamic and carboxylic acid derivatives
ATE342257T1 (de) 1999-08-27 2006-11-15 Chemocentryx Inc Heterozyclische verbindungen und verfahren zur modulierung von cxcr3 funktion
GB9920910D0 (en) 1999-09-03 1999-11-10 Indena Spa Novel chalcones
GB9920912D0 (en) 1999-09-03 1999-11-10 Indena Spa Novel derivatives of flavones,xanthones and coumarins
ES2234662T3 (es) 1999-09-16 2005-07-01 Curis, Inc. Mediadores de rutas de señalizacion hedgehog, composiciones y usos relacionados con los mismos.
US6552016B1 (en) 1999-10-14 2003-04-22 Curis, Inc. Mediators of hedgehog signaling pathways, compositions and uses related thereto
NZ518480A (en) * 1999-10-27 2004-02-27 Cytokinetics Inc Methods and compositions utilizing quinazolinones
US6545004B1 (en) * 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
US6683192B2 (en) 2000-03-30 2004-01-27 Curis, Inc. Small organic molecule regulators of cell proliferation
US6559145B2 (en) 2000-07-12 2003-05-06 Pharmacia & Upjohn Company Heterocycle carboxamides as antiviral agents
IL156304A0 (en) 2000-12-11 2004-01-04 Tularik Inc Cxcr3 antagonists
PL366799A1 (en) 2001-07-27 2005-02-07 Curis, Inc. Mediators of hedgehog signaling pathways, compositions and uses related thereto
SE0103648D0 (sv) 2001-11-01 2001-11-01 Astrazeneca Ab Therapeutic quinolone compounds
US7060705B2 (en) 2001-11-07 2006-06-13 Merck & Co., Inc. Mitotic kinesin inhibitors
US20050107404A1 (en) 2001-12-06 2005-05-19 Fraley Mark E. Mitotic kinesin inhibitors
WO2003049527A2 (en) 2001-12-06 2003-06-19 Merck & Co., Inc. Mitotic kinesin inhibitors
JP2005515208A (ja) 2001-12-06 2005-05-26 メルク　エンド　カムパニー　インコーポレーテッド 有糸分裂性キネシン阻害剤
ATE372341T1 (de) 2001-12-06 2007-09-15 Merck & Co Inc Inhibitoren von mitotischem kinesin
EP1481077B1 (de) 2001-12-06 2009-11-04 Merck & Co., Inc. Mitotische kinesin-hemmer
ATE448207T1 (de) 2002-03-08 2009-11-15 Merck & Co Inc Mitotische kinesin-hemmer
MXPA04010240A (es) 2002-04-17 2005-06-08 Cytokinetics Inc Compuestos, composiciones y metodos.
CA2483627A1 (en) 2002-05-23 2003-12-04 Merck & Co., Inc. Mitotic kinesin inhibitors
WO2003106417A1 (en) 2002-06-14 2003-12-24 Merck & Co., Inc. Mitotic kinesin inhibitors
CN100421665C (zh) 2002-06-14 2008-10-01 麦克公司 有丝分裂驱动蛋白抑制剂
JP2005537257A (ja) 2002-07-08 2005-12-08 メルク　エンド　カムパニー　インコーポレーテッド 有糸分裂キネシン結合部位
US6949538B2 (en) * 2002-07-17 2005-09-27 Cytokinetics, Inc. Compounds, compositions, and methods
WO2004014388A1 (en) * 2002-08-13 2004-02-19 Warner-Lambert Company Llc 6,6-fused heteroaryl derivatives as matrix metalloproteinase inhibitors
EP1670456A2 (de) * 2003-10-06 2006-06-21 Cytokinetics, Inc. Verbindungen, zusammensetzungen und verfahren
WO2005040163A1 (en) * 2003-10-28 2005-05-06 Dr. Reddy's Laboratories Ltd Heterocyclic compounds that block the effects of advanced glycation end products (age)

Also Published As

Publication number Publication date
WO2004006865A3 (en) 2004-07-01
AU2003252025A8 (en) 2004-02-02
JP2005533119A (ja) 2005-11-04
US20040116400A1 (en) 2004-06-17
EP1539727B1 (de) 2009-02-18
US6949538B2 (en) 2005-09-27
AU2003252025A1 (en) 2004-02-02
EP1539727A4 (de) 2007-04-04
DE60326248D1 (de) 2009-04-02
WO2004006865A2 (en) 2004-01-22
US20060004073A1 (en) 2006-01-05
EP1539727A2 (de) 2005-06-15

Similar Documents

Publication Publication Date Title
WO2003103575A3 (en) COMPOUNDS, COMPOSITIONS AND METHODS
MY140767A (en) Compounds, methods and compositions
MY140169A (en) Compounds, compositions, and methods
WO2004018058A3 (en) Compounds, compositions, and methods
MXPA06012796A (es) Ciertas entidades quimicas, composiciones y metodos.
DE60326248D1 (de) Verbindungen, zusammensetzungen und verfahren zur behandlung von zellulären proliferativen erkrankungen
WO2004009036A3 (en) Compounds compositions and methods
WO2006113432A3 (en) Compounds, compositions and methods
DE60118544D1 (de) Methoden und zusammensetzungen zur modulation der aktivität der alpha-adrenergen rezeptoren
EA200900802A1 (ru) Способы и композиции для лечения амилоидных заболеваний
DE602004017736D1 (de) Verwendung von rapamycin und dessen derivaten zur behandlung von knochenverlust
EA200600078A1 (ru) Способы и композиции для лечения амилоидных заболеваний
ATE448775T1 (de) Rifalazil zur behandlung von infektionen mit clostridium difficile
DE60112766D1 (de) Verwendung von derivaten der valproinsäureamide und 2-valproinsäureamid zur behandlung und prävention von schmerzen und/oder kopfschmerzen
ATE288747T1 (de) Methoden und zusammensetzungen zur modulierung der aktivität von alpha-adrenergen rezeptoren
DE60103171D1 (de) Verfahren und verbindungen zur behandlung proliferativer erkrankungen
NO20052267L (no) Forbindelser, Preparater og Metoder
WO2004034972A3 (en) Compounds, compositions, and methods
WO2005046588A3 (en) Compounds, compositions, and methods
WO2004064741A3 (en) Compounds, compositions, and methods
DE602004021363D1 (de) Imidazotriazin verbindungen zur behandlung von krebserkrankungen
WO2004100873A3 (en) Compounds, compositions, and methods
WO2005042697A3 (en) Compounds, compositions and methods
WO2004024086A3 (en) Compounds, compositions and methods
WO2004032879A3 (en) Compounds, compositions, and methods

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties